One-year enzyme-linked immunosorbent assay follow-up of human interleukin for Da cells/leukemia inhibitory factor in blood and urine of 22 kidney transplant recipients.
The cytokine human interleukin for Da cells/leukemia inhibitory factor (HILDA/LIF) exerts multiple biological effects in vitro. In mice, high circulating levels of HILDA/LIF induce a wide range of pathophysiological events, some of them closely involved with immunological and inflammatory responses. Using a sandwich ELISA recognizing the natural human HILDA/LIF molecule with a threshold of 50 pg/ml in urine and 150 pg/ml in plasma, we monitored the urine and plasma HILDA/LIF levels of 22 patients in their first year after a kidney transplant. HILDA/LIF urine excretion is increased during acute rejection, and infections also trigger heavy HILDA/LIF plasma concentrations or urine excretion. In addition, this study raises the question of HILDA/LIF involvement in post-kidney-transplant phenomena such as hypercalcemia, osteoporosis, or the reversal of anemia.
Morel
D
D
Service de Néphrologie, Hôpital Pellegrin, Bordeaux, France.
Taupin
J L
JL
Combe
C
C
Potaux
L
L
Gualde
N
N
Moreau
J F
JF
D000293:Adolescent; D000328:Adult; D001002:Anuria / Q000209:etiology; D005260:Female; D006084:Graft Rejection; D006131:Growth Inhibitors / Q000097:blood* / Q000652:urine*; D006801:Humans; D015850:Interleukin-6; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology / Q000502:physiology*; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000097:blood* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013514:Surgical Procedures, Operative; D013997:Time Factors
D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines